Correction to “Characterization of Dasatinib and its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways”

In the article referenced above [ Li X, He Y, Ruiz CH, Koenig M, and Cameron MD (2009) Drug Metab Dispos37:1242–1250], for contributions to the chemistry required to synthesize analogs of dasatinib, Tomas Vojkovsky should be considered a co-author.

The authors regret this error and apologize for any inconvenience or confusion it may have caused.